Skip to Content
Merck
  • IL-33 receptor ST2 regulates the cognitive impairments associated with experimental cerebral malaria.

IL-33 receptor ST2 regulates the cognitive impairments associated with experimental cerebral malaria.

PLoS pathogens (2017-04-28)
Flora Reverchon, Stéphane Mortaud, Maëliss Sivoyon, Isabelle Maillet, Anthony Laugeray, Jennifer Palomo, Céline Montécot, Améziane Herzine, Sandra Meme, William Meme, François Erard, Bernhard Ryffel, Arnaud Menuet, Valérie F J Quesniaux
ABSTRACT

Cerebral malaria (CM) is associated with a high mortality rate and long-term neurocognitive impairment in survivors. The murine model of experimental cerebral malaria (ECM) induced by Plasmodium berghei ANKA (PbA)-infection reproduces several of these features. We reported recently increased levels of IL-33 protein in brain undergoing ECM and the involvement of IL-33/ST2 pathway in ECM development. Here we show that PbA-infection induced early short term and spatial memory defects, prior to blood brain barrier (BBB) disruption, in wild-type mice, while ST2-deficient mice did not develop cognitive defects. PbA-induced neuroinflammation was reduced in ST2-deficient mice with low Ifng, Tnfa, Il1b, Il6, CXCL9, CXCL10 and Cd8a expression, associated with an absence of neurogenesis defects in hippocampus. PbA-infection triggered a dramatic increase of IL-33 expression by oligodendrocytes, through ST2 pathway. In vitro, IL-33/ST2 pathway induced microglia expression of IL-1β which in turn stimulated IL-33 expression by oligodendrocytes. These results highlight the IL-33/ST2 pathway ability to orchestrate microglia and oligodendrocytes responses at an early stage of PbA-infection, with an amplification loop between IL-1β and IL-33, responsible for an exacerbated neuroinflammation context and associated neurological and cognitive defects.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Olig-2 Antibody, Chemicon®, from rabbit